Cesca Therapeutics Company Profile (NASDAQ:KOOL)

About Cesca Therapeutics

Cesca Therapeutics logoCesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company's therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KOOL
  • CUSIP:
Key Metrics:
  • Previous Close: $2.88
  • 50 Day Moving Average: $3.02
  • 200 Day Moving Average: $3.36
  • 52-Week Range: $1.85 - $7.39
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.27
  • P/E Growth: 0.00
  • Market Cap: $29.46M
  • Outstanding Shares: 9,886,000
  • Beta: -0.66
Profitability:
  • Net Margins: -297.49%
  • Return on Equity: -37.44%
  • Return on Assets: -25.80%
Debt:
  • Current Ratio: 3.09%
  • Quick Ratio: 2.24%
Additional Links:
Companies Related to Cesca Therapeutics:

Analyst Ratings

Consensus Ratings for Cesca Therapeutics (NASDAQ:KOOL) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Cesca Therapeutics (NASDAQ:KOOL)
Show:
DateFirmActionRatingPrice TargetDetails
12/5/2016Maxim GroupReiterated RatingHoldView Rating Details
9/21/2015HC WainwrightUpgradeNeutral -> Buy$2.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Cesca Therapeutics (NASDAQ:KOOL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017        
2/16/2016Q216($0.07)($0.02)$4.32 million$3.29 millionViewListenView Earnings Details
11/16/2015Q116($0.06)($0.08)$3.71 million$2.80 millionViewListenView Earnings Details
9/17/2015Q415($0.11)($0.06)$3.70 millionViewListenView Earnings Details
6/23/2015Q315($0.08)($0.12)$4.00 millionViewListenView Earnings Details
2/12/2015Q215($0.08)($0.11)$4.08 million$4.60 millionViewN/AView Earnings Details
11/13/2014Q115($0.08)$3.60 million$3.70 millionViewN/AView Earnings Details
9/29/2014Q414($0.06)($0.09)$4.30 millionViewN/AView Earnings Details
5/15/2014($0.05)($0.07)ViewN/AView Earnings Details
2/14/2014Q214($0.10)$4.80 million$4.50 millionViewN/AView Earnings Details
11/14/2013Q1($0.14)ViewListenView Earnings Details
8/29/2013Q4 2013($0.14)$4.50 million$4.10 millionViewN/AView Earnings Details
11/13/2012Q113$0.06$4.90 million$4.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cesca Therapeutics (NASDAQ:KOOL)
Current Year EPS Consensus Estimate: $-1.18 EPS
Next Year EPS Consensus Estimate: $-1.27 EPS

Dividends

Dividend History for Cesca Therapeutics (NASDAQ:KOOL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cesca Therapeutics (NASDAQ:KOOL)
Insider Ownership Percentage: 26.60%
Institutional Ownership Percentage: 2.30%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/26/2016(Hong Kong) Ltd BoyalifeMajor ShareholderBuy6,102,942$2.52$15,379,413.84View SEC Filing  
11/10/2015Kenneth HarrisDirectorSell80,858$0.60$48,514.80View SEC Filing  
11/9/2015Kenneth HarrisDirectorSell48,468$0.60$29,080.80View SEC Filing  
11/6/2015Kenneth HarrisDirectorSell30,190$0.60$18,114.00View SEC Filing  
11/3/2015Kenneth HarrisDirectorSell10,510$0.60$6,306.00View SEC Filing  
11/2/2015Kenneth HarrisDirectorSell5,700$0.60$3,420.00View SEC Filing  
10/29/2015Kenneth HarrisDirectorSell8,632$0.60$5,179.20View SEC Filing  
9/2/2015Matthew T. PlavanCEOSell17,271$0.68$11,744.28View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cesca Therapeutics (NASDAQ:KOOL)
DateHeadline
News IconRevenue Update on Cesca Therapeutics Inc(NASDAQ:KOOL) - Money Flow Index & Trends (NASDAQ:KOOL)
www.moneyflowtrends.com - February 24 at 9:56 AM
marketexclusive.com logoCESCA THERAPEUTICS INC. (NASDAQ:KOOL) Files An 8-K Financial Statements and Exhibits (NASDAQ:KOOL)
marketexclusive.com - February 20 at 5:36 PM
finance.yahoo.com logoCESCA THERAPEUTICS INC. Financials (NASDAQ:KOOL)
finance.yahoo.com - February 17 at 4:22 PM
biz.yahoo.com logoCESCA THERAPEUTICS INC. Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:KOOL)
biz.yahoo.com - February 17 at 4:22 PM
News IconOracle Corporation (NYSE:ORCL) Earns Average Broker Rating Of Outperform (NASDAQ:KOOL)
naijaoversabi.com - February 14 at 7:38 PM
baystreet.ca logoCesca Therapeutics (KOOL) Falls on Q2 Loss (NASDAQ:KOOL)
www.baystreet.ca - February 14 at 7:38 PM
4-traders.com logoLEXUS : TO UNVEIL THE ALL-NEW LS 500h AT THE 2017 GENEVA MOTOR SHOW (NASDAQ:KOOL)
www.4-traders.com - February 14 at 5:18 AM
marketexclusive.com logoCESCA THERAPEUTICS INC. (NASDAQ:KOOL) Files An 8-K Results of Operations and Financial Condition (NASDAQ:KOOL)
marketexclusive.com - February 14 at 5:18 AM
finance.yahoo.com logoCesca Therapeutics Reports Second Quarter Fiscal 2017 Financial Results and Provides Business Update (NASDAQ:KOOL)
finance.yahoo.com - February 13 at 7:16 PM
biz.yahoo.com logoCESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E (NASDAQ:KOOL)
biz.yahoo.com - February 13 at 7:16 PM
biz.yahoo.com logoQ2 2017 Cesca Therapeutics Inc Earnings Release - After Market Close (NASDAQ:KOOL)
biz.yahoo.com - February 13 at 10:46 AM
News IconCesca Therapeutics Inc. (NASDAQ:KOOL) is Attracting Smart Money - Small Cap Exclusive (press release) (NASDAQ:KOOL)
smallcapexclusive.com - February 10 at 12:14 AM
News IconKOOL – Cesca Therapeutics Inc - Men's News Daily (NASDAQ:KOOL)
mensnewsdaily.com - February 9 at 7:09 PM
News IconKeen Investors Taking a Look at Cesca Therapeutics Inc. (NASDAQ ... - Prospect Journal (NASDAQ:KOOL)
prospectjournal.com - February 1 at 5:00 AM
News IconIs the Needle Ready to Move for Cesca Therapeutics Inc. (NASDAQ:KOOL) - Prospect Journal (NASDAQ:KOOL)
prospectjournal.com - February 1 at 5:00 AM
News IconCesca Therapeutics Inc KOOL Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:KOOL)
www.bioportfolio.com - January 29 at 6:30 PM
News IconAre Cagey Traders Interested in These Shares: Cesca Therapeutics Inc. (NASDAQ:KOOL) - Prospect Journal (NASDAQ:KOOL)
prospectjournal.com - January 26 at 7:56 PM
News IconBrokers Release Average Price Target Of 3.33 On Cesca Therapeutics Inc. (KOOL) - UK Market News (NASDAQ:KOOL)
www.ukmarketnews.co.uk - January 25 at 7:36 PM
bizjournals.com logoSacramento medical equipment developer raises $500,000 in most recent financing round (NASDAQ:KOOL)
www.bizjournals.com - January 24 at 6:55 PM
prnewswire.com logoIPOs and Transactions: Jan 16 – 20 / plus “SEC Reporting & Filing in the Trump Administration” webinar (NASDAQ:KOOL)
irblog.prnewswire.com - January 23 at 10:36 AM
finance.yahoo.com logoCesca Therapeutics Appoints Dr. Joseph Thomis to Its Board of Directors (NASDAQ:KOOL)
finance.yahoo.com - January 17 at 12:07 PM
News IconCesca Therapeutics Inc. (KOOL) - Product Pipeline Analysis, Size ... - Medgadget (blog) (NASDAQ:KOOL)
www.medgadget.com - January 7 at 8:24 PM
streetinsider.com logoCesca Therapeutics (KOOL) IDE Supplement for Phase III Clinical Trial Approved by FDA - StreetInsider.com (NASDAQ:KOOL)
www.streetinsider.com - January 6 at 12:33 AM
streetinsider.com logoCesca Therapeutics (KOOL) IDE Supplement for Phase III Clinical Trial Approved by FDA (NASDAQ:KOOL)
www.streetinsider.com - January 5 at 7:31 PM
finance.yahoo.com logo6:05 am Cesca Therapeutics receives FDA approval for significant revisions to its pivotal study for treatment of Critical Limb Ischemia (NASDAQ:KOOL)
finance.yahoo.com - January 5 at 7:30 PM
publicnow.com logoCESCA ANNOUNCES FDA APPROVAL OF IDE SUPPLEMENT FOR PHASE III CLINICAL TRIAL (NASDAQ:KOOL)
www.publicnow.com - January 5 at 7:30 PM
News IconStock Spotlight: Checking on Shares of Cesca Therapeutics Inc ... - Wall Street Beacon (NASDAQ:KOOL)
wsbeacon.com - January 3 at 9:46 PM
globenewswire.com logoCesca Therapeutics to Present at the 9th Annual Biotech Showcase ... - GlobeNewswire (press release) (NASDAQ:KOOL)
globenewswire.com - January 3 at 9:46 PM
finance.yahoo.com logoCesca Therapeutics to Present at the 9th Annual Biotech Showcase (NASDAQ:KOOL)
finance.yahoo.com - January 3 at 11:17 AM
News IconForeigners among victims of Istanbul attack (NASDAQ:KOOL)
vouxmagazine.com - January 2 at 6:07 PM
247wallst.com logoInsiders Keep Buying as Market Wraps on 2016: Tronic, Six Flags, Virtu Financial, Cesca Therapeutics and More - 24/7 Wall St. (NASDAQ:KOOL)
247wallst.com - January 2 at 10:04 AM
News IconCesca Therapeutics Inc (NASDAQ:KOOL) Re-Energized Heading into 2017 - The Oracle Dispatch (NASDAQ:KOOL)
oracledispatch.com - January 2 at 10:04 AM
News IconHot Performer of the day: Cesca Therapeutics Inc. (NASDAQ:KOOL) (NASDAQ:KOOL)
diy-home-garden.com - January 1 at 11:18 PM
News IconAnalysts Advise About Cesca Therapeutics Inc. (NASDAQ:KOOL) (NASDAQ:KOOL)
viveremilano.biz - January 1 at 11:18 PM
News IconCesca Therapeutics (KOOL) Stock: Here's Why It's Soaring - CNA Finance (press release) (NASDAQ:KOOL)
cnafinance.com - December 31 at 6:01 PM
rttnews.com logoCesca Therapeutics Inc. (KOOL) Is Surging In Early Trade (NASDAQ:KOOL)
www.rttnews.com - December 29 at 6:14 PM
marketexclusive.com logoInsider Trading Activity Cesca Therapeutics Inc. (NASDAQ:KOOL) – Hong Kong) Ltd Boyalife (Major Shareholder ... - Market Exclusive (NASDAQ:KOOL)
marketexclusive.com - December 29 at 7:43 AM
4-traders.com logoInsider Trading Activity Cesca Therapeutics Inc. (NASDAQ:KOOL) – Hong Kong) Ltd Boyalife (Major Shareholder Bought 6,102,942 shares of Stock (NASDAQ:KOOL)
www.4-traders.com - December 28 at 11:15 PM
News IconBargain or Bait? Stock Update on Cesca Therapeutics Inc. (NASDAQ:KOOL) - Prospect Journal (NASDAQ:KOOL)
prospectjournal.com - December 23 at 11:26 PM
News IconCan This Stock Pick Up Any Momentum: Cesca Therapeutics Inc. (NASDAQ:KOOL) - Prospect Journal (NASDAQ:KOOL)
prospectjournal.com - December 22 at 12:01 AM
News IconInvestor Corner: Checking the Numbers on Cesca Therapeutics Inc. (NASDAQ:KOOL) - Liberty News (NASDAQ:KOOL)
libertynewsrecord.com - December 22 at 12:01 AM
News IconInvestors are Following Shares of Cesca Therapeutics Inc. (NASDAQ:KOOL) - OIB News (NASDAQ:KOOL)
oibnews.com - December 21 at 6:23 AM
News IconBargain Hunters Should Take a Look at Cesca Therapeutics Inc. (NASDAQ:KOOL) - Prospect Journal (NASDAQ:KOOL)
prospectjournal.com - December 21 at 6:23 AM
biz.yahoo.com logoCESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib (NASDAQ:KOOL)
biz.yahoo.com - December 21 at 6:23 AM
News IconROIC Focus on Shares of Cesca Therapeutics Inc. (NASDAQ:KOOL ... - Business Daily Leader (NASDAQ:KOOL)
businessdailyleader.com - December 18 at 11:26 PM
News IconInvestor Wire: Keeping an Eye on Cesca Therapeutics Inc. (NASDAQ:KOOL) - OIB News (NASDAQ:KOOL)
oibnews.com - December 16 at 11:49 PM
streetinsider.com logoCesca Therapeutics (KOOL) Announces Submission of CLI IDE Supplement to FDA - StreetInsider.com (NASDAQ:KOOL)
www.streetinsider.com - December 7 at 3:22 PM
us.rd.yahoo.com logoCesca Submits IDE Supplement for CLI Pivotal Trial (NASDAQ:KOOL)
us.rd.yahoo.com - December 5 at 10:40 AM
us.rd.yahoo.com logo6:01 am Cesca Therapeutics submits an Investigational Device Exemption Supplement to the FDA for its previously approved CLI pivotal trial (NASDAQ:KOOL)
us.rd.yahoo.com - December 5 at 10:40 AM
News IconStock Tracker: Focusing on Shares of Cesca Therapeutics Inc. (NASDAQ:KOOL) - Liberty News (NASDAQ:KOOL)
libertynewsrecord.com - December 3 at 11:36 AM

Social

What is Cesca Therapeutics' stock symbol?

Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."

When will Cesca Therapeutics announce their earnings?

Cesca Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 10th 2017.

How do I buy Cesca Therapeutics stock?

Shares of Cesca Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cesca Therapeutics stock cost?

One share of Cesca Therapeutics stock can currently be purchased for approximately $2.88.

Cesca Therapeutics (NASDAQ:KOOL) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Cesca Therapeutics (NASDAQ:KOOL)

Earnings History Chart

Earnings by Quarter for Cesca Therapeutics (NASDAQ:KOOL)

Dividend History Chart

Dividend Payments by Quarter for Cesca Therapeutics (NASDAQ:KOOL)

Last Updated on 2/24/2017 by MarketBeat.com Staff